2011
DOI: 10.1089/ars.2010.3234
|View full text |Cite
|
Sign up to set email alerts
|

Insulin Signaling and Insulin Sensitizing in Muscle and Liver of Obese Monkeys: Peroxisome Proliferator-Activated Receptor Gamma Agonist Improves Defective Activation of Atypical Protein Kinase C

Abstract: Obesity, the metabolic syndrome, and aging share several pathogenic features in both humans and non-human primates, including insulin resistance and inflammation. Since muscle and liver are considered key integrators of metabolism, we sought to determine in biopsies from lean and obese aging rhesus monkeys the nature of defects in insulin activation and, further, the potential for mitigation of such defects by an in vivo insulin sensitizer, rosiglitazone, and a thiazolidinedione activator of the peroxisome pro… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

2
5
0

Year Published

2011
2011
2023
2023

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 12 publications
(7 citation statements)
references
References 91 publications
2
5
0
Order By: Relevance
“…These dysmetabolic monkeys did not have overt type 2 diabetes. Thus, we have documented that hepatic insulin resistance as a whole (in comparison to hepatic insulin signaling) appears to not be as late of an event in the progression to overt diabetes as previously suggested using pharmacological insulin doses [ 3 , 6 , 8 ], although the more severe peripheral insulin resistance in these monkeys agrees with the notion that it does develop first [ 41 ].…”
Section: Discussionsupporting
confidence: 79%
See 1 more Smart Citation
“…These dysmetabolic monkeys did not have overt type 2 diabetes. Thus, we have documented that hepatic insulin resistance as a whole (in comparison to hepatic insulin signaling) appears to not be as late of an event in the progression to overt diabetes as previously suggested using pharmacological insulin doses [ 3 , 6 , 8 ], although the more severe peripheral insulin resistance in these monkeys agrees with the notion that it does develop first [ 41 ].…”
Section: Discussionsupporting
confidence: 79%
“…Unfortunately without biopsies or magnetic resonance spectroscopy data, this remains only a hypothesis. It must also be noted that it has previously been shown that while there is no defect in insulin’s regulation of hepatic glycogen metabolism in dysmetabolic monkeys [ 6 ], there is a defect in insulin-stimulated protein kinase B (PKB/Akt) activity [ 8 ], perhaps suggesting that hepatic insulin resistance in them may manifest in the regulation of gluconeogenesis via PKB and forkhead box protein O1[ 40 ]. These dysmetabolic monkeys did not have overt type 2 diabetes.…”
Section: Discussionmentioning
confidence: 99%
“…Phase II clinical trial data in patients with T2DM demonstrated that body weight increased to a lesser extent with aleglitazar, when compared with pioglitazone in a head-to-head comparison study [32]. Although the direct comparison between aleglitazar and pioglitazone was not performed in our study, previous thiazolidinediones studies in rhesus monkeys [15,33] support the notion that gains in body weight would be less evident with aleglitazar.…”
Section: Discussionsupporting
confidence: 49%
“…In the liver, insulin actions include activation of insulin receptor substrate (IRS)-1-dependent phosphoinositide 3-kinase (PI 3-kinase), protein kinase B/Akt [26] and forkhead box O1 (Foxo1), in which a major role of hepatic Akt is to restrain the activity of Foxo1 [27] . Decrease in Trx/TrxR is associated with insulin resistance, suggesting potential role of insulin signaling in mediating this process.…”
Section: Resultsmentioning
confidence: 99%